Inactive Instrument

News Kadimastem TEL AVIV STOCK EXCHANGE

Stocks

KDST

IL0011284614

Biotechnology & Medical Research

All News

07-01	NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes	AQ
07-01	NewcelX Ltd. Announces Successful FDA Pre-IND Meeting With Clear Path Forward For NCEL-101 Toward Starting Clinical Trials For Type 1 Diabetes	CI
06-15	NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential Of Its Stem Cell Technology Platform	CI
05-27	Newcelx submits pre-IND package to FDA for NCEL-101 for treatment of type 1 diabetes	RE
05-27	NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes	GL
05-27	NewcelX Submits Pre-IND Package To FDA For NCEL-101 For The Treatment Of Type 1 Diabetes	CI
04-30	NewcelX Ltd. announced that it has received $1.349994 million in funding	CI
04-29	NewcelX Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-28	NewcelX Ltd. Auditor Raises 'Going Concern' Doubt	CI
04-20	Newcelx updates corporate presentation to highlight type 1 diabetes flagship program	RE
04-20	NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference	GL
04-01	NewcelX Ltd. announced that it expects to receive $1.349994 million in funding	CI
04-01	NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing	GL
03-09	NewcelX announces strategic collaboration with Eledon Pharmaceuticals to advance NCEL-101 program for type 1 diabetes	RE
03-09	NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes	PR
02-12	NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy	PR
01-12	NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression	PR
01-12	Newcelx Ltd. Announces Positive Results from International Collaborative Study	CI
01-05	NewcelX Ltd. Announces Appointment Of Dr. Julien Boisdron To Scientific Advisory Board	CI
01-05	NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board	PR
12-11	NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China	PR
11-17	NewcelX Ltd. Announces Appointment of Prof. Jeremy Shefner to the Scientific Advisory Board	CI
11-07	NewcelX Ltd. Announces Chief Financial Officer Changes, Effective December 10, 2025	CI
11-06	NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board	PR
11-06	NewcelX Ltd. Appoints Tamir Ben-Hur as Scientific Advisory Board	CI